 HYDERABAD, India--BUSINESS WIRE--Dr. Reddys Laboratories Ltd. BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as Dr. Reddys today announced that it has initiated the process with the Drugs Controller General of India DCGI for Emergency Use Authorization EUA of the well-studied human adenoviral vector-based platform vaccine candidate, Sputnik V. As part of the review process, Dr. Reddys will present the safety profile of the pha 